Sairah Ahmed
A5039574726- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Multiple Myeloma Research and Treatments
- Viral-associated cancers and disorders
- CNS Lymphoma Diagnosis and Treatment
- Immune Cell Function and Interaction
- Polyomavirus and related diseases
- Biosimilars and Bioanalytical Methods
- Cutaneous lymphoproliferative disorders research
- Lung Cancer Treatments and Mutations
- T-cell and Retrovirus Studies
- Protein Degradation and Inhibitors
- Viral Infectious Diseases and Gene Expression in Insects
- Cancer Immunotherapy and Biomarkers
- Integrated Circuits and Semiconductor Failure Analysis
- Childhood Cancer Survivors' Quality of Life
- Peptidase Inhibition and Analysis
- Virus-based gene therapy research
- Histone Deacetylase Inhibitors Research
- Cancer Treatment and Pharmacology
The University of Texas MD Anderson Cancer Center
2016-2025
Sylvester Comprehensive Cancer Center
2024
Fred Hutch Cancer Center
2024
City Of Hope National Medical Center
2024
Moffitt Cancer Center
2024
Prisma Health
2024
City of Hope
2024
The University of Texas Health Science Center at San Antonio
2024
Cornell University
2024
Abu Dhabi National Oil (United Arab Emirates)
2023
Allogeneic stem cell transplantation for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) has been performed primarily an HLA-matched donor. Outcomes of haploidentical have recently improved, a comparison between donor sources in uniform cohort not performed. We evaluated outcomes 227 AML/MDS treated melphalan-based conditioning. Donors were matched related (MRD) (n = 87, 38%), unrelated (MUD) 108, 48%), or 32, 14%). No significant differences found MUD...
Abstract The impact of bridging therapy (BT) administered between leukapheresis and chimeric antigen receptor (CAR) T-cell for large B-cell lymphoma (LBCL) is unclear. We evaluated the influence BT (systemic [ST], radiation [RT], or combined-modality [CMT]) on outcomes 148 LBCL patients who underwent planned axicabtagene ciloleucel (axi-cel) infusion. 55% (n = 81) received were more likely to have international prognostic index (IPI) score ≥3 (P ≤ .01), bulky disease elevated lactate...
Multiple myeloma (MM) is a disease with known immune dysregulation. Natural killer (NK) cells have shown preclinical activity in MM. We conducted first-in-human study of umbilical cord blood-derived (CB) NK for MM patients undergoing high dose chemotherapy and autologous haematopoietic stem cell transplantation (auto-HCT). Patients received lenalidomide (10 mg) on days −8 to −2, melphalan 200 mg/m2 day −7, CB-NK −5 auto-HCT 0. Twelve were enrolled, three each four levels: 5 × 106, 1 107, 107...
Despite unprecedented efficacy, 1 the use of axicabtagene ciloleucel (axi-cel) for treatment patients with relapsed or refractory large B-cell lymphoma (LBCL) remains associated acute toxicity, such as grade $3 cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity (ICANS), occurring in 11% 32% patients, respectively. 2Analysis 44 different analytes serum LBCL treated axi-cel showed that an increase IL-6 IL-1 may be toxicity. 3However, 2 murine models, whereas...
T cell-mediated hyperinflammatory responses, such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity (ICANS), are now well-established toxicities of chimeric antigen receptor (CAR) cell therapy. As the field CAR cells advances, however, there is increasing recognition that hemophagocytic lymphohistiocytosis (HLH)-like following infusion occurring broadly across patient populations constructs. Importantly, these HLH-like often not directly associated with CRS...
Axicabtagene ciloleucel (axi-cel) is a standard-of-care for patients with relapsed or refractory (r/r) large B cell lymphoma who have received 2 more lines of prior therapy. Patients receiving axi-cel in the real world could broader demographic, disease, and treatment profile compared that cohort pivotal ZUMA-1 trial. The present study was conducted to evaluate outcomes therapy real-world setting. A total 1297 commercial between 2017 2020 were selected from Center International Blood Marrow...
LBA4 Background: The addition of BV to initial chemotherapy improves overall survival (OS) in adults and PFS pediatric patients (pts) with AS HL. However, frontline adds toxicity, most pts receive radiation therapy (RT), 7-20% still develop relapsed/refractory (RR) PD-1 pathway is central the pathogenesis HL blockade effective RR adult cooperative groups National Clinical Trials Network (NCTN) conducted randomized, phase 3 S1826 trial evaluate N-AVD vs BV-AVD newly diagnosed Methods:...
BackgroundIncorporating brentuximab vedotin into the treatment of advanced-stage classic Hodgkin's lymphoma improves outcomes in adult and pediatric patients. However, increases toxic effects adults, more than half patients who receive drug undergo consolidative radiation, relapse remains a challenge. Programmed death 1 blockade is effective lymphoma, including preliminary studies involving previously untreated patients.MethodsWe conducted phase 3, multicenter, open-label, randomized trial...
JC virus, the cause of progressive multifocal leukoencephalopathy (PML), and BK virus are genetically similar share sequence homology in immunogenic proteins. We treated three immunosuppressed patients with PML ex vivo-expanded, partially HLA-matched, third-party-produced, cryopreserved virus-specific T cells. The immunosuppression these was due to conditioning regimen for cord-blood transplantation one patient, a myeloproliferative neoplasm ruxolitinib another, acquired immunodeficiency...
Recognizing the significant biological and clinical heterogeneity of mature T cell natural killer (NK)/T lymphomas, American Society for Blood Marrow Transplantation invited experts to develop practice recommendations related role autologous hematopoietic transplantation (auto-HCT) allogeneic HCT (allo-HCT) specific histological subtypes. We used GRADE methodology aid in moving from evidence decision making ultimately generating final recommendations. Auto-HCT front-line consolidation is...
Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 may be associated with long-term adverse effects such as cytopenia and immune deficiency. In order to characterize these late events, we analyzed 31 patients relapsed or refractory large B-cell lymphoma treated axicabtagene ciloleucel at our institution on two clinical trials, ZUMA-1 (clinicaltrials gov. Identifier: NCT02348216) ZUMA-9 NCT03153462). Complete blood counts, lymphocyte subsets, immunoglobulin levels were measured...
PurposeFew studies to date have evaluated factors associated with the development of radiation pneumonitis (RP) in patients Hodgkin lymphoma (HL) and non-Hodgkin (NHL), especially treated contemporary techniques. These represent a unique group owing often large target volumes within mediastinum potential receive several lines chemotherapy that add pulmonary toxicity for relapsed or refractory disease. Our objective was determine incidence clinical dosimetric risk RP intensity modulated...
Highlights•Patients with follicular lymphoma (FL) experiencing early therapy failure (ETF) within 2 years of frontline chemoimmunotherapy have poor overall survival (OS).•FL patients ETF receiving autoHCT soon after treatment (≤1 year ETF; n = 123) had higher 5-year OS than those without (73% versus 60%).AbstractPatients (OS). We analyzed data from the Center for International Blood and Marrow Transplant Research (CIBMTR) National LymphoCare Study (NLCS) to determine whether autologous...
The Endothelial Activation and Stress Index (EASIX) score, defined as [(creatinine × lactate dehydrogenase [LDH])/platelets], is a marker of endothelial activation that has been validated in the allogeneic hematopoietic stem cell transplant setting. one mechanisms driving immune-mediated toxicities patients treated with chimeric antigen receptor-T (CAR-T)-cell therapy. This study's objective was to evaluate association between EASIX other laboratory parameters collected before...
Neurotoxicity or immune effector cell-associated neurotoxicity syndrome (ICANS) is the second most common acute toxicity after chimeric antigen receptor (CAR) T-cell therapy. However, there are limited data on clinical and radiologic correlates of ICANS. We conducted a cohort analysis 100 consecutive patients with relapsed refractory large B-cell lymphoma (LBCL) treated standard care axicabtagene ciloleucel (axi-cel). ICANS was graded according to an objective grading system. Neuroimaging...
<h3>Importance</h3> Primary central nervous system lymphoma (PCNSL) requires induction and consolidation to achieve potential cure. High-dose therapy autologous hematopoietic cell transplant (AHCT) is an accepted effective strategy for PCNSL, but no consensus exists on the optimal conditioning regimens. <h3>Objective</h3> To assess outcomes in patients with PCNSL undergoing AHCT 3 most commonly used regimens: thiotepa/busulfan/cyclophosphamide (TBC), thiotepa/carmustine (TT-BCNU),...
Allogeneic hematopoietic cell transplantation (alloHCT) can potentially salvage large B-cell lymphoma (LBCL) patients experiencing treatment failure after chimeric antigen receptor T-cell therapy (CAR T). Nonetheless, data on the efficacy and toxicities of alloHCT receipt CAR T are limited. We report a multicenter retrospective study assessing safety, toxicities, outcomes in LBCL following failure. Eighty-eight with relapsed, refractory received an anti-CD19 The median number lines between...